Compare Novo Nordisk A/S (NVO) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Royal Caribbean Cruises Ltd — how do they compare? Novo Nordisk A/S trades at $46.2 (market cap $207.85B), while Royal Caribbean Cruises Ltd trades at $307.59 (market cap $82.15B). The key difference: Novo Nordisk A/S is far larger — about 2.5× Royal Caribbean Cruises Ltd's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | RCL | |
|---|---|---|
Market Cap | $207.85B | $82.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $365.84 |
52-Week Low | $35.29 | $246.71 |
Enterprise Value | $222.55B | $104.79B |
Dividend Yield | 3.81% | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Royal Caribbean (RCL) trades at $309.24, up 0.4% with a bullish technical signal. The company shows strong fundamental momentum with Q2 2026 EPS beating expectations at $4.21 vs. $3.98 estimate, and revenue growth accelerating from $8.8B in 2022 to $17.9B in 2025. Net income margin improved to 23.54% while ROE stands at 45.33%. Recent news highlights strong demand and record pricing for 2027 bookings, though geopolitical concerns have slightly tempered European outlook.
RCL presents a compelling growth story with robust earnings momentum and analyst consensus pointing to 11% upside to the $343.09 price target. Key risks include geopolitical impacts on European itineraries, elevated debt levels at $18.47B long-term, and capital-intensive fleet expansion. The stock's premium valuation at P/E 18.97 requires continued execution on growth targets to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
